SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Namiki S, Satoh T, Baba S et al. Quality of life after brachytherapy or radical prostatectomy for localized prostate cancer: a prospective longitudinal study. Urology 2006; 68: 12306
  • 2
    Cesaretti JA, Kao J, Stone NN, Stock RG. Effect of low dose-rate prostate brachytherapy on the sexual health of men with optimal sexual function before treatment: analysis at > or = 7 years of follow-up. BJU Int 2007; 100: 3627
  • 3
    Critz FA, Williams WH, Benton JB, Levinson AK, Holladay CT, Holladay DA. Prostate specific antigen bounce after radioactive seed implantation followed by external beam radiation for prostate cancer. J Urol 2000; 163: 10859
  • 4
    Stock RG, Stone NN, Cesaretti JA. Prostate-specific antigen bounce after prostate seed implantation for localized prostate cancer: descriptions and implications. Int J Radiat Oncol Biol Phys 2003; 56: 44853
  • 5
    Bostancic C, Merrick GS, Butler WM et al. Isotope and patient age predict for PSA spikes after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 2007; 68: 14317
  • 6
    Ishiyama H, Kitano M, Satoh T et al. Difference in rectal dosimetry between pre-plan and post-implant analysis in transperineal interstitial brachytherapy for prostate cancer. Radiother Oncol 2006; 78: 1948
  • 7
    Rivard MJ, Coursey BM, DeWerd LA et al. Update of AAPM Task Group, No. 43 Report: a revised AAPM protocol for brachytherapy dose calculations. Med Phys 2004; 31: 63374
  • 8
    Mytrle JF, Klimley PG, Ivor L et al. Clinical utility of prostate specific antigen (PSA) in the management of prostate cancer. In Advances in Cancer Diagnostics. San Diego: Hybritech Inc, 1986: 14
  • 9
    Merrick GS, Butler WM, Galbreath RW, Lief JH. Five-year biochemical outcome following permanent interstitial brachytherapy for clinical T1–T3 prostate cancer. Int J Radiat Oncol Biol Phys 2001; 51: 418
  • 10
    Crook J, Gillan C, Yeung I, Austen L, McLean M, Lockwood G. PSA kinetics and PSA bounce following permanent seed prostate brachytherapy. Int J Radiat Oncol Biol Phys 2007; 69: 42633
  • 11
    Cesaretti JA, Stone NN, Stock RG. Urinary symptom flare following I-125 prostate brachytherapy. Int J Radiat Oncol Biol Phys 2003; 56: 108592
  • 12
    Lehrer S, Cesaretti J, Stone NN, Stock RG. Urinary symptom flare after brachytherapy for prostate cancer is associated with erectile dysfunction and more urinary symptoms before implantation. BJU Int 2006; 98: 97981
  • 13
    Rosser CJ, Kamat AM, Wang X et al. Is patient age a factor in the occurrence of prostate-specific antigen bounce phenomenon after external beam radiotherapy for prostate cancer? Urology 2005; 66: 32731
  • 14
    Lepor H, Wang B, Shapiro E. Relationship between prostatic epithelial volume and serum prostate-specific antigen levels. Urology 1994; 44: 199205
  • 15
    Fukatsu A, Ono Y, Ito M et al. Relationship between serum prostate-specific antigen and calculated epithelial volume. Urology 2003; 61: 3704
  • 16
    Tchetgen MB, Song JT, Strawderman M, Jacobsen SJ, Oesterling JE. Ejaculation increases the serum prostate-specific antigen concentration. Urology 1996; 47: 5116